Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 31Lung Neoplasms 9Small Cell Lung Carcinoma 7Biliary Tract Neoplasms 7Carcinoma, Hepatocellular 6Urinary Bladder Neoplasms 4Liver Neoplasms 4Carcinoma 4Neoplasm Metastasis 3Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma Extensive Disease 2Recurrence 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Non-Muscle Invasive Bladder Neoplasms 2Gallbladder Neoplasms 2Endometrial Neoplasms 2Carcinoma, Renal Cell 2Urothelial Cancer 1Sarcoma 1Radiation Pneumonitis 1Pancoast Syndrome 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Non Small Cell Lung Carcinoma NSCLC 1Non Small Cell Lung Cancer NSCLC 1Non - Small Cell Lung Cancer NSCLC 1Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1

Interventions

Pemetrexed 2Gemcitabine 2Cisplatin 2Carboplatin 2CP protocol 2durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Non Small Cell Lung Carcinoma NSCLC × durvalumab × Clear all
NCT03003962 2026-03-11

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

AstraZeneca

Phase 3 Active not recruiting
669 enrolled 54 charts
Thoracic

Non Small Cell Lung Carcinoma NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡